Ceplene® (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival, while maintaining good quality of life during treatment. Ceplene acts by enhancing the immunostimulatory effect of IL-2 and countering reactive oxygen species-induced dysfunction and apoptosis of T and NK cells, thereby inducing immune-mediated killing of leukemic cells, providing a strong rationale for this combination therapy. Ceplene is approved in over 30 countries and has received Orphan Drug Designation in the United States and in the European Union.  In June 2017, Immune re-acquired European rights to Ceplene from Meda, a Mylan NV company.

Azixa® (veribulin) is a novel microtubule destabilizer that acts as a vascular disrupting agent. It is capable of evading multidrug resistance pumps and, thus, achieves high CNS concentrations.  It is efficacious in multiple xenograft models without CNS toxicity. 169 patients have been treated to date with Azixa® in multiple phase 1 and phase 2 clinical trials and Preliminary clinical effect was demonstrated in patients with brain tumors, melanoma as well as other solid tumors. Azixa has Orphan Drug Designation in the United States for the treatment of glioblastoma.

Crolibulin is a a novel microtubule destabilizer and vascular disrupting agent for the intended treatment of patients with solid tumors. In preclinical animal tumor models, combination therapy has demonstrated synergistic activity with cytotoxic drugs as well as anti-angiogenic drugs, such as Avastin. Crolibulin has demonstrated positive clinical effect in a phase 2 study in anaplastic thyroid cancer  under a National Cancer Institute collaboration.  To date over 100 patients have been treated with Crolibulin.

Immune currently seeks to divest its oncology assets.